Literature DB >> 15496957

Gene therapy progress and prospects: gene therapy for diabetes mellitus.

V Yechoor1, L Chan.   

Abstract

Diabetes mellitus has long been targeted, as yet unsuccessfully, as being curable with gene therapy. The main hurdles have not only been vector-related toxicity but also the lack of physiological regulation of the expressed insulin. Recent advances in understanding the developmental biology of beta-cells and the transcriptional cascade that drives it have enabled both in vivo and ex vivo gene therapy combined with cell therapy to be used in animal models of diabetes with success. The associated developments in the stem cell biology and immunology have opened up further opportunities for gene therapy to be applied to target autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15496957     DOI: 10.1038/sj.gt.3302412

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  9 in total

Review 1.  Minireview: beta-cell replacement therapy for diabetes in the 21st century: manipulation of cell fate by directed differentiation.

Authors:  Vijay Yechoor; Lawrence Chan
Journal:  Mol Endocrinol       Date:  2010-03-10

2.  Failure to achieve normal metabolic response in non-obese diabetic mice and streptozotocin-induced diabetic mice after transplantation of primary murine hepatocytes electroporated with the human proinsulin gene (p3MTChins).

Authors:  R H Lee; G Roll; V Nguyen; H Willenbring; Q Tang; S-M Kang; P G Stock
Journal:  Transplant Proc       Date:  2014 Jul-Aug       Impact factor: 1.066

Review 3.  Chronic diabetic complications: the body's adaptive response to hyperglycemia gone awry?

Authors:  Lawrence Chan; Tomoya Terashima; Mineko Fujimiya; Hideto Kojima
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

4.  Gene therapy with neurogenin 3 and betacellulin reverses major metabolic problems in insulin-deficient diabetic mice.

Authors:  Vijay Yechoor; Victoria Liu; Antoni Paul; Jeongkyung Lee; Eric Buras; Kerem Ozer; Susan Samson; Lawrence Chan
Journal:  Endocrinology       Date:  2009-10-09       Impact factor: 4.736

5.  Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment.

Authors:  Mina Rasouli; Zalinah Ahmad; Abdul Rahman Omar; Zeenathul N Allaudin
Journal:  BMC Biotechnol       Date:  2011-11-03       Impact factor: 2.563

6.  Antibody-mediated oral delivery of therapeutic DNA for type 2 diabetes mellitus.

Authors:  Seungbin Cha; Sun Hwa Lee; Sung Hun Kang; Mohammad Nazmul Hasan; Young Jun Kim; Sungpil Cho; Yong-Kyu Lee
Journal:  Biomater Res       Date:  2018-07-27

7.  Femtosecond laser treatment enhances DNA transfection efficiency in vivo.

Authors:  Shaw-Wei D Tsen; Chao-Yi Wu; Avedis Meneshian; Sara I Pai; Chien-Fu Hung; T-C Wu
Journal:  J Biomed Sci       Date:  2009-04-01       Impact factor: 8.410

8.  Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model.

Authors:  Nelson K F Chen; Jen San Wong; Irene H C Kee; Siang Hui Lai; Choon Hua Thng; Wai Har Ng; Robert T H Ng; Soo Yong Tan; Shu Yen Lee; Mark E H Tan; Jaichandran Sivalingam; Pierce K H Chow; Oi Lian Kon
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

9.  Emblic Leafflower (Phyllanthus emblica L.) Fruits Ameliorate Vascular Smooth Muscle Cell Dysfunction in Hyperglycemia: An Underlying Mechanism Involved in Ellagitannin Metabolite Urolithin A.

Authors:  Junxuan Zhou; Cong Zhang; Guo-Hua Zheng; Zhenpeng Qiu
Journal:  Evid Based Complement Alternat Med       Date:  2018-03-06       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.